One To Watch
Nicox
Company Overview
A French ophthalmology biotech whose lead asset, NCX 470, has an FDA PDUFA date of April 30, 2027, placing Nicox on the threshold of its first US approval for a novel glaucoma treatment. Nicox SA is listed on Euronext Paris under the ticker COX and concentrates its research on nitric oxide-donating chemistry applied to eye disease. The company discovered and developed NCX 470, built two pivotal Phase III trial programs, then structured a partnership network to handle US and Asian commercialization.
Headquarters and Global Presence
Nicox is headquartered in Sophia Antipolis, France. Its commercial and regulatory footprint is global by design: licensing arrangements cover the United States, Japan, China, and the majority of Southeast Asia, meaning the company does not carry the cost of building its own sales forces in those markets.
Founding and History
Nicox built its early pipeline around nitric oxide-donating versions of established ophthalmic agents, applying the chemistry to both glaucoma and allergic eye disease. The company previously brought VYZULTA (latanoprostene bunod) to commercialization, subsequently licensing it to Bausch + Lomb.
Therapy Areas and Focus
Nicox focuses almost entirely on ophthalmology, with glaucoma and ocular hypertension as the primary commercial target. Open-angle glaucoma remains a high-volume, chronically under-controlled condition: existing prostaglandin analogs lower intraocular pressure through a single outflow pathway, leaving room for agents that engage two simultaneously.
Dry eye disease represents a secondary focus through NCX 4251, following FDA feedback directing the program toward that indication.
Technology Platforms and Modalities
Nicox's defining approach is nitric oxide donation: appending a nitric oxide-releasing moiety to an established ophthalmic molecule to create a dual-mechanism agent. In the case of NCX 470, nitric oxide relaxes the trabecular meshwork to enhance conventional aqueous outflow, while the bimatoprost component drives uveoscleral outflow. The logic is that engaging both drainage pathways delivers meaningfully greater intraocular pressure reduction than either mechanism alone.
VYZULTA, now commercialized by Bausch + Lomb, validated this approach for latanoprost; NCX 470 applies the same framework to bimatoprost.
Key Pipeline and Programs
NCX 470 (bimatoprost grenod, also known as K-911) is a 0.1% nitric oxide-donating bimatoprost ophthalmic solution being developed for open-angle glaucoma and ocular hypertension. It is the company's lead asset and reached Phase III through two pivotal trials: the Mont Blanc study and the Denali study. The NDA, filed by licensee Kowa Pharmaceuticals America in July 2026, was accepted by the FDA with a PDUFA target action date of April 30, 2027.
NCX 4251 is a fluticasone propionate ophthalmic suspension (0.1%) in development for dry eye disease, a direction confirmed following an FDA meeting. A Phase IIb trial, named Mississippi, produced positive post hoc results in a subgroup of patients dosed once daily, though the primary study had earlier produced a disappointing result.
Recent Developments
The most consequential milestone came on August 27, 2026, when the FDA accepted the NCX 470 NDA for filing, triggering a 3 million euro milestone payment from Kowa Pharmaceuticals America to Nicox. The NDA submission itself followed the Denali trial read-out in August 2025, which confirmed non-inferiority to latanoprost, and the subsequent July 2025 licensing agreement under which Kowa took on US regulatory and commercialization responsibility.
Key Personnel
Doug Hubatsch serves as chief scientific officer, overseeing non-clinical and clinical development activities.
Strategic Partnerships
Kowa Company holds the license for NCX 470 in the United States and Japan; its US affiliate, Kowa Pharmaceuticals America, submitted and owns the NDA and is responsible for commercialization. Bausch + Lomb holds the license for VYZULTA (latanoprostene bunod), an earlier nitric oxide-donating prostaglandin analog that Nicox originally developed.
FAQ Section
If the FDA approves NCX 470 by April 30, 2027, Nicox will be entitled to milestone and royalty payments from Kowa Pharmaceuticals America without carrying US sales infrastructure costs itself. The PDUFA date is the single most important near-term event on Nicox's calendar.
Standard prostaglandins such as latanoprost lower intraocular pressure primarily through the uveoscleral pathway; trabecular outflow, which accounts for a large share of drainage, is largely unaffected. NCX 470 couples bimatoprost's uveoscleral action with nitric oxide-mediated relaxation of the trabecular meshwork, engaging both simultaneously.
VYZULTA pairs nitric oxide donation with latanoprost, while NCX 470 uses bimatoprost as its prostaglandin backbone. Bimatoprost has historically shown strong intraocular pressure lowering, and the combination with a nitric oxide moiety is designed to build on that. Kowa's commercial weight in Japan and the US, absent from the VYZULTA arrangement with Bausch + Lomb, also gives NCX 470 a different partner profile as it approaches launch.
Two pivotal Phase III trials, Mont Blanc and Denali, compared NCX 470 0.1% against latanoprost 0.005% as the active comparator. Mont Blanc data were presented at the 2025 American Glaucoma Society meeting, with further pre-planned analyses also published.
Dry eye disease is the secondary focus, addressed by NCX 4251, a fluticasone propionate ophthalmic suspension. Following FDA feedback, Nicox directed NCX 4251 specifically toward that indication; the Phase IIb Mississippi trial produced positive post hoc results in once-daily dosed patients, though the primary study outcome was disappointing. Allergic conjunctivitis is a legacy area through Zerviate, now licensed to Ocumension for certain Asian markets.
Nicox is at a late-stage regulatory position: the lead asset's NDA is under active FDA review with a decision expected April 30, 2027. The immediate milestone is a standard review cycle with no announced request for advisory committee input. Beyond the FDA decision, Ocumension's regulatory processes in China and Southeast Asia represent the next geographic approval opportunity, and the NCX 4251 dry eye program requires further Phase II work to build a credible filing package.
The company's value inflection points and risks are concentrated and near-term.
Today's issue
| Headless Content Management with Blaze